Eric PasqualottoDouglas Mesadri GewehrRafael Oliva Morgado FerreiraMatheus Pedrotti ChavezCaroliny SilvaSara Almeida CruzJhonny Limachi-ChoqueAmanda ParkMário Sérgio Soares de Azeredo CoutinhoLuiz Fernando Kubrusly2026-03-222026-03-22202410.36660/abc.20230738https://doi.org/10.36660/abc.20230738https://andeanlibrary.org/handle/123456789/85878Citaciones: 1DOACs had a similar rate of thromboembolic and hemorrhagic events, as well as thrombus resolution, compared to VKAs in the treatment of LVTs. Rivaroxaban therapy had a significant reduction in thromboembolic events, compared to VKAs.ptMedicineGynecologyInternal medicineGastroenterologyreview